Dulaglutide Tracker App
Track Trulicity Doses, HbA1c, and Weekly Progress in Shotlee
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes, available in four doses from 0.75 mg to 4.5 mg. As a GLP-1 Fc fusion protein with a 5-day half-life, it delivers consistent weekly GLP-1 receptor stimulation with a hidden-needle autoinjector. The REWIND trial demonstrated cardiovascular benefit across a broad T2D population. Track every weekly dose and lab result in Shotlee.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free
What Is Dulaglutide?
Dulaglutide (brand name Trulicity) is a GLP-1 Fc fusion protein developed by Eli Lilly and approved by the FDA in September 2014. Unlike GLP-1 analogues (liraglutide, semaglutide) which are structurally modified forms of native GLP-1, dulaglutide consists of two GLP-1 molecules linked to a modified human IgG4 Fc region. This architecture reduces renal clearance and extends the half-life to approximately 5 days — enabling reliable once-weekly dosing.
The mechanism is identical to other GLP-1 receptor agonists: stimulation of the GLP-1 receptor increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and reduces hypothalamic appetite signals. Dulaglutide is delivered via a single-dose, pre-filled autoinjector with a hidden needle — a feature that has made it popular among patients with needle aversion who would otherwise avoid injectable GLP-1 therapy entirely.
Broad CV Evidence from REWIND
The REWIND trial is notable for including 31.5% primary-prevention patients (no prior CV event). Dulaglutide reduced MACE by 12% in this broad population, extending GLP-1 CV benefit evidence beyond the high-risk cohorts studied in LEADER and SUSTAIN-6.
Dulaglutide Dose Schedule
0.75 mg
Weeks 1–4 (starting dose)
Initiation dose to improve tolerability. Administer once weekly on the same day. Establish injection day routine from week 1.
1.5 mg
Week 5+ (maintenance)
Standard maintenance dose. AWARD-1: -1.51% HbA1c. Adequate for most patients with T2D.
3.0 mg
Escalation (additional control)
For patients requiring additional HbA1c reduction beyond 1.5 mg. Added in 2020 US label update.
4.5 mg
Maximum dose
Maximum approved dose. AWARD-11 showed additional -0.3% HbA1c vs 1.5 mg. Highest weight reduction in the dulaglutide range.
Dulaglutide Clinical Data Highlights
MACE reduction (REWIND)
-12%
Relative reduction in cardiovascular events in REWIND (HR 0.88, p=0.026) over 5.4 years in 9,901 T2D patients.
HbA1c reduction (AWARD-1)
-1.51%
Mean HbA1c reduction at 1.5 mg vs placebo at 26 weeks in AWARD-1. Comparable to other GLP-1 agents at similar doses.
Weight change (AWARD-1)
-1.3 kg
Mean body weight reduction vs placebo with dulaglutide 1.5 mg at 26 weeks in AWARD-1.
What to Track in Shotlee
Weekly dulaglutide injections pair well with weekly check-ins — use Shotlee to build a consistent weekly tracking routine.
Weekly Injection Logs
Record each dose, date, and injection site. Log on the same day each week for consistent tracking against your dose day.
HbA1c at Clinic Visits
Enter lab HbA1c results from every clinic visit. Dulaglutide efficacy is typically reassessed every 3 months.
Weekly Body Weight
Track weight weekly (same day, same conditions). Dulaglutide produces modest weight loss — quantify your personal response.
CV Markers
Log blood pressure, cholesterol, and eGFR. REWIND showed MACE and renal benefits beyond glucose lowering.
GI Side Effects
Nausea, diarrhoea, and abdominal pain peak in the first weeks and during escalation. Log timing and severity.
Dose Consistency
Track your injection day over time. Consistent weekly timing maintains steady-state dulaglutide levels.
Protocol FAQs
Dulaglutide (Trulicity) is a GLP-1 Fc fusion protein; semaglutide (Ozempic/Wegovy) is a GLP-1 analogue. Both are once-weekly GLP-1 receptor agonists. Head-to-head trials (SUSTAIN 7) show semaglutide achieves greater HbA1c reduction (-1.8% vs -1.4%) and weight loss (-6.5 kg vs -3.0 kg) at comparable doses.
The REWIND trial (9,901 T2D patients, 5.4 years) showed dulaglutide reduced 3-point MACE by 12% vs placebo. This included a broad population — 31.5% had no prior CV event — extending cardiovascular benefit beyond the high-risk populations studied in earlier GLP-1 trials.
Yes. Biosimilar dulaglutide has been approved in some markets, providing a lower-cost alternative to branded Trulicity. Availability varies by country and insurance coverage. Biosimilar versions should have the same clinical effect as the originator.
Once weekly on the same day each week. The day can be changed as long as doses remain at least 3 days apart. Use Shotlee to log your injection day and receive weekly reminders.
Nausea (12–21%), diarrhoea (8–14%), vomiting (5–9%), and abdominal pain (9–11%) are most common during dose initiation and escalation. These typically resolve within 4–6 weeks. Log side effects in Shotlee with timing and severity to track resolution.
References
- [1]Clinical TrialGerstein HC, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)." Lancet. 2019;394(10193):121-130.
- [2]Clinical TrialWysham C, et al. "Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes (AWARD-1)." Diabetes Care. 2014;37(8):2159-2167.
Track Your Dulaglutide Protocol in Shotlee
Log weekly injections, HbA1c, cardiovascular markers, and side effects — free in Shotlee.
🚀 Use Shotlee for Free